Skip to content

Pharma

Oyster Point Pharma Goes Public

OIS INDEX Oyster Point

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has been $19.01, while its low has been $15.16. Look for Oyster Point to join the OIS Index in the next report. Oyster Point Pharma’s lead product candidate, OC-01, a highly…

Read More

Digging deep in the retina pipeline

Digging deep in the retina pipeline

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early phase research at OIS@AAO may provide a glimpse of what will be the buzz five or 10 years from now, if not sooner. They include a fully degradable implant to…

Read More

Ain’t Misbehaving

Ain’t Misbehaving

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The next day, it closed at $20.15. On Oct. 21, the day’s high was $20.70; it closed at $19.59. Is this any way for Aerie’s stock to behave? The company launched…

Read More

Protocol V, LEAVO Among Retina Highlights at ARVO 2019

Protocol V, LEAVO Among Retina Highlights at ARVO

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear first-time results from two highly anticipated studies on diabetic macular edema (DME) and vein occlusion. The much anticipated Protocol V results were made public at an evening symposium from the…

Read More

Will Dexycu’s Cost Inhibit Its Use?

Will Dexycu’s Cost Inhibit Its Use?

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a single dose, instead of the usual corticosteroid eye drops he sends home with patients to treat their postoperative inflammation. But at a list price about 10 times higher than those…

Read More

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make its pitch that its cannabinoid-based therapy may succeed where others have failed – to effectively harness the benefits of marijuana in lowering intraocular pressure (IOP) without the side effects. Nemus…

Read More

Nicox Patiently Pursues Moves to Build Value

Nicox Patiently Pursues Moves to Build Value

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials, with one of them recently licensed for development and commercialization in China. And while the company pulled back last fall from listing on NASDAQ, it hasn’t scrapped that plan and…

Read More

Lessons and Pearls for Moving the Dry Eye Space Forward

Lessons and Pearls for Moving the Dry Eye Space Forward

Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was expensive. The team decided to abandon the program, realizing that it was no longer realistic to think the device would receive a high-dollar CPT code to cover the cost of…

Read More

Explaining the Explosion in the Dry Eye Space

Explaining the Explosion in the Dry Eye Space

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest in this topic. As session moderator Preeya Gupta, MD, of Duke University Eye Center said, 10 years ago there wasn’t much of a market for dry eye or much innovation…

Read More
Scroll To Top